James C Yang, M.D.
National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name James C Yang, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:41 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03745326 · Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 PatientsNational Cancer Institute (NCI) · terminated · Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer · principal investigator
- Ph1/Ph2NCT03190941 · Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsNational Cancer Institute (NCI) · recruiting · Pancreatic Cancer, Gastric Cancer, Gastrointestinal Cancer · principal investigator
- Ph1/Ph2NCT02830724 · Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersNational Cancer Institute (NCI) · recruiting · Pancreatic Cancer, Renal Cell Cancer, Breast Cancer · principal investigator
- Ph1/Ph2NCT02390739 · Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid CancerNational Cancer Institute (NCI) · withdrawn · Metastatic Thyroid Cancer · principal investigator
- Ph2NCT02133196 · T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung CancerNational Cancer Institute (NCI) · recruiting · Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC · principal investigator
- Ph1NCT00923390 · Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 ReceptorNational Cancer Institute (NCI) · terminated · Renal Cancer, Kidney Cancer · principal investigator
- Ph1NCT00304460 · Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney CancerNational Cancer Institute (NCI) · completed · Metastatic Melanoma, Renal Cell Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 19 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.